An Invasive Disease Event-Free Survival Analysis to Investigate Ki67 Role with Respect to Breast Cancer Patients' Age: A Retrospective Cohort Study.
IDEFS
Kaplan–Meier
invasive breast cancer
ki67
survival analysis
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
28 Apr 2022
28 Apr 2022
Historique:
received:
24
03
2022
revised:
21
04
2022
accepted:
27
04
2022
entrez:
14
5
2022
pubmed:
15
5
2022
medline:
15
5
2022
Statut:
epublish
Résumé
Characterization of breast cancer into intrinsic molecular profiles has allowed women to live longer, undergoing personalized treatments. With the aim of investigating the relation between different values of ki67 and the predisposition to develop a breast cancer-related IDE at different ages, we enrolled 900 patients with a first diagnosis of invasive breast cancer, and we partitioned the dataset into two sub-samples with respect to an age value equal to 50 years. For each sample, we performed a Kaplan−Meier analysis to compare the IDE-free survival curves obtained with reference to different ki67 values. The analysis on patients under 50 years old resulted in a p-value < 0.001, highlighting how the behaviors of patients characterized by a ki67 ranging from 10% to 20% and greater than 20% were statistically significantly similar. Conversely, patients over 50 years old characterized by a ki67 ranging from 10% to 20% showed an IDE-free survival probability significantly greater than patients with a ki67 greater than 20%, with a p-value of 0.01. Our work shows that the adoption of two different ki67 values, namely, 10% and 20%, might be discriminant in designing personalized treatments for patients under 50 years old and over 50 years old, respectively.
Identifiants
pubmed: 35565344
pii: cancers14092215
doi: 10.3390/cancers14092215
pmc: PMC9104454
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Nat Rev Dis Primers. 2019 Sep 23;5(1):66
pubmed: 31548545
J Clin Oncol. 2007 May 20;25(15):2127-32
pubmed: 17513820
Breast Cancer Res Treat. 2011 Nov;130(2):489-98
pubmed: 21837481
S Afr J Surg. 2016 Jun;54(2):10-13
pubmed: 28240498
Metabolism. 2015 Mar;64(3 Suppl 1):S16-21
pubmed: 25468140
World J Clin Oncol. 2014 Aug 10;5(3):382-92
pubmed: 25114853
Diagnostics (Basel). 2021 Apr 10;11(4):
pubmed: 33920221
Prz Menopauzalny. 2015 Sep;14(3):196-202
pubmed: 26528110
Pathology. 2017 Feb;49(2):166-171
pubmed: 28065411
BMC Cancer. 2016 Sep 15;16(1):734
pubmed: 27634735
Crit Rev Oncol Hematol. 2014 Sep;91(3):223-33
pubmed: 24725667
BMJ. 2004 May 1;328(7447):1073
pubmed: 15117797
Sci Rep. 2020 May 6;10(1):7648
pubmed: 32376868
Clin Cancer Res. 2019 Mar 15;25(6):1970-1979
pubmed: 30559169
Ann Surg Oncol. 2015 Oct;22(11):3481-8
pubmed: 25652052
Lancet Oncol. 2010 Feb;11(2):174-83
pubmed: 20152769
BMC Med. 2015 Aug 17;13:195
pubmed: 26278220
Breast. 2016 Oct;29:109-16
pubmed: 27479041
Lancet. 2002 May 11;359(9318):1686-9
pubmed: 12020548
Bioinformatics. 2012 Jan 1;28(1):112-8
pubmed: 22039212
Breast. 2007 Aug;16(4):327-43
pubmed: 17499991
J Clin Pathol. 2013 Jun;66(6):512-6
pubmed: 23436927
Breast Care (Basel). 2013 May;8(2):102-9
pubmed: 24000280
Anesth Analg. 2018 Sep;127(3):792-798
pubmed: 30015653
Semin Oncol. 2009 Jun;36(3):237-49
pubmed: 19460581
World J Surg Oncol. 2015 Feb 07;13:33
pubmed: 25889186